查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158987

病毒增強劑市場：全球市場預測，2026-2032年

Viral Transduction Enhancer Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病毒介導的增強子市場將成長至 2.9892 億美元，複合年成長率為 11.71%。

主要市場統計數據
基準年 2025 1.3762億美元
預計年份：2026年 1.539億美元
預測年份 2032 2.9892億美元
複合年成長率 (%) 11.71%

病毒誘導增強劑：執行摘要和研究範圍

病毒遞送增強劑是指用於提高病毒載體向目標細胞遞送效率的試劑、製劑和製程輔助劑。它們的重要性體現在研究、生物製程開發、基因修飾細胞生產和病毒載體製造等領域。市場需求源自於在提高遞送效率的同時，維持細胞活力、產品品質、可重複性和符合監管要求。本概述不提供市場估算或預測，而是重點關注影響該領域的科學、運營、區域和政策因素。

從實驗最佳化到可控制造流程

當前趨勢正從孤立的實驗室最佳化轉向標準化、可擴展的工作流程。使用者越來越重視增強劑的評估，並將其與載體類型、細胞狀態、感染複數、暴露時間、培養基條件和下游回收率等因素結合起來考慮。操作的重點包括：在不同供體和細胞株間保持性能一致性、與懸浮和貼壁培養系統相容、易於去除和稀釋，以及清晰的成分和生產控制記錄。這些要求需要能夠整合到已驗證流程中的解決方案，而不是作為獨立的性能增強劑。

利用人工智慧 (AI) 加速篩檢、設計和製程控制

人工智慧 (AI) 可以透過對實驗條件進行排序、識別載體與細胞參數之間的相互作用以及減少試驗錯次數來促進病毒介導基因轉移技術的開發。機器學習模型可以輔助進行基於影像的轉移效率、細胞活力和細胞形態評估，而製程分析可以偵測批次間的差異。然而，有效利用人工智慧需要高品質、可追溯的資料集和具有生物學意義的終點指標。人工審核對於解釋模型輸出、管理因訓練資料有限而產生的偏差以及證明人工智慧驅動的決策適用於受監管的開發仍然至關重要。

區域洞察：基礎設施、監管和製造業成熟度

在北美，先進的細胞和基因治療研究、成熟的生物製程能力以及對可重複且擴充性試劑的強勁需求共同推動了生物技術的發展。在歐洲，重點在於品質系統、可追溯性和各國監管環境的一致性。亞太地區受惠於不斷擴展的生物製造能力和研發活動，其中中國、日本、韓國、印度和澳洲等國家擁有重要的研發中心。拉丁美洲的特點是專業基礎設施、本地製造能力以及對成本效益高的製程解決方案的需求存在差異。中東地區選擇性地投資於生物技術和先進醫療保健能力，而非洲的生物技術應用則受到基礎設施建設、人力資源開發以及可靠的冷鍊和實驗室系統的影響。

團體洞察：夥伴關係塑造標準、可近性和能力

東南亞國協擁有多元化的新興生物製造能力、研究網路和成熟的監管體系，為協調一致的培訓和採購慣例創造了機會。金磚國家擁有重要的研發生態系統和正在發展中的生物技術市場，因此技術轉移和本地能力建設至關重要。歐盟受益於監管協調和跨境科學合作。七國集團（G7）國家普遍擁有先進的研究基礎設施和成熟的品管系統。海灣合作理事會（GCC）成員國正透過投資和機構間夥伴關係，建構生物技術和醫療保健能力。北約成員國擁有廣泛的科學和工業基礎，並將供應鏈韌性、生物安全和可靠的生產能力作為優先合作領域。

國家概況：主要市場部署重點各異

美國和加拿大優先發展轉化研究、商業規模的生物程序以及嚴格的品質文件。英國、法國、德國、義大利和西班牙將學術優勢與不斷擴大的先進治療藥物生產相結合，並以歐盟監管框架下的通用品質標準為支持。中國正在提升其國內生物技術和製程開發能力。日本和韓國優先發展高品質的生產、自動化和精確的製程控制。印度在加強生物製藥生產和研發的同時，也努力平衡成本效益和監管合規性。澳洲支持先進的生物醫學研究和專業製造夥伴關係。巴西和墨西哥仍然是拉丁美洲的關鍵樞紐，但准入、在地化生產、人才培養和技術轉移仍然是其面臨的主要挑戰。俄羅斯的生物技術活動受到國內供應優先事項、研發能力以及不斷變化的國際合作格局的影響。

病毒載體製程開發領域領導者可採取的優先事項

產業領導者應透過整合式實驗設計方案評估增強劑，該方案應全面測量下游製程中的轉導效率、細胞活力、表現型、載體完整性和產品品質。他們還應制定供應商合格標準，涵蓋成分、批間一致性、文件記錄、無菌或微生物附著量控制以及變更通知流程。研發團隊應儘早檢驗增強劑在相關細胞來源和規模下的性能，而不是僅在小規模研究環境中進行最佳化。監管和技術團隊應清楚記錄增強劑的識別資訊、使用情況、去除策略和風險評估。最後，各組織應制定區域供應鏈緊急應變計畫，投資於分析可比性，並僅在檢驗的數據和受控的工作流程中，在人工監督下使用人工智慧。

調查方法：基於證據的質性市場評估

本執行摘要採用結構化的定性評估方法，對病毒載體增強劑領域進行分析。分析內容涵蓋應用需求、製程開發挑戰、監管和品質考量、人工智慧應用案例、基礎設施狀況以及區域生物技術能力等多個面向。區域、群體和國家層級的觀察結果均基於公認的產業和政策特徵，而非專有估計值。本摘要不包含市場規模估算、市佔率計算、預測或公司排名。結論應作為策略背景進行解讀，並需參考最新的科學文獻、監管指南、採購數據以及組織特定的流程結果檢驗。

結論：可重複性和一致性決定了競爭優勢。

隨著開發者致力於在複雜的細胞和載體系統中實現可靠的遞送，病毒轉導增強子的重要性日益凸顯。該領域的發展方向並非取決於轉導率的孤立提升，而是取決於能否提供可重複的性能、維持細胞健康、支持可擴展的生產以及滿足品質預期。區域能力、統一的標準、穩健的供應鏈以及人工智慧的合理應用將顯著影響其應用。那些將增強子選擇與端到端流程控制和證據生成相結合的領導企業，將在將實驗室成果轉化為穩健的治療和生物製造工作流程方面擁有顯著優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：病毒增強劑市場：依產品類型分類

  • 陽離子脂質
    • 脂質體轉染劑
    • 轉染
  • 陽離子聚合物
    • DEAE-聚葡萄糖
    • 聚氯乙烯
    • 硫酸魚精蛋白
  • 樹狀聚合物
  • 基於胜肽的
    • Chariot
    • MPG

第8章：病毒增強劑市場：依載體類型分類

  • AAV
    • 自互補型
    • 單鏈
  • 腺病毒
    • 具備複製能力
    • 拷貝不足的字形
  • 慢病毒
    • 第一代
    • 第二代
    • 第三代
  • 逆轉錄病毒

第9章：病毒增強劑市場：依工作流程階段分類

  • 下游工藝
    • 配方
    • 純化
  • 品管
    • 向量嵌入分析
    • 存活率檢驗
  • 轉導
    • 細胞培養
      • 黏合劑類型
      • 懸浮培養
    • 轉導最佳化
    • 病毒生產
      • 放大
      • 病毒滴度測定
  • 上游工程
    • 細胞增殖
    • 培養基的製備

第10章：病毒增強劑市場：依應用分類

  • Ex Vivo
    • 造血幹細胞
    • T細胞
  • 原位
  • 體內
    • 肌肉骨骼系統
    • 神經系統
    • 眼科

第11章：病毒增強劑市場：以最終用戶分類

  • 學術機構
    • 研究中心
    • 大學
  • 生物製藥公司
  • 受託研究機構
    • 臨床階段
    • 臨床前階段
  • 醫院檢查室

第12章：病毒增強劑市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：病毒增強劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：病毒增強劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Aldevron, LLC
  • Applied Biological Materials Inc.
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • GenScript Biotech Corporation
  • Horizon Discovery Group plc
  • Lonza Group Ltd.
  • MaxCyte
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Mirus Bio
  • Oxford Biomedica plc
  • OZ Biosciences
  • Polyplus-transfection SA
  • Promega Corporation
  • Revvity
  • Sino Biological Inc.
  • SIRION Biotech GmbH
  • TaKaRa Bio Inc.
  • Thermo Fisher Scientific Inc.

第17章 主要專家

Product Code: MRR-4654A89DBBF5

The Viral Transduction Enhancer Market is projected to grow by USD 298.92 million at a CAGR of 11.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 137.62 million
Estimated Year [2026] USD 153.90 million
Forecast Year [2032] USD 298.92 million
CAGR (%) 11.71%

Viral Transduction Enhancers: Executive Summary and Scope

Viral transduction enhancers are reagents, formulation components, and process aids used to improve the delivery of viral vectors into target cells. Their relevance spans research, bioprocess development, gene-modified cell production, and viral-vector manufacturing. Demand is shaped by the need to increase delivery efficiency while preserving cell viability, product quality, reproducibility, and regulatory control. This summary focuses on scientific, operational, geographic, and policy factors influencing the field without presenting market estimates or forecasts.

From Experimental Optimization to Controlled Manufacturing Workflows

The landscape is shifting from one-off laboratory optimization toward standardized, scalable workflows. Users increasingly evaluate enhancers alongside vector type, cell state, multiplicity of infection, exposure duration, media conditions, and downstream recovery. The most important operational priorities are consistent performance across donor and cell-line variability, compatibility with suspension and adherent systems, ease of removal or dilution, and clear documentation of composition and manufacturing controls. These requirements favor solutions that can be integrated into validated processes rather than treated as isolated performance additives.

Artificial Intelligence Accelerates Screening, Design, and Process Control

Artificial intelligence can strengthen viral-transduction development by ranking experimental conditions, identifying interactions among vector and cell parameters, and reducing the number of trial-and-error runs. Machine-learning models can also support image-based assessment of transduction, viability, and cell morphology, while process analytics can flag drift between batches. However, useful deployment depends on high-quality, traceable datasets and biologically meaningful endpoints. Human review remains essential for interpreting model outputs, managing bias from limited training data, and demonstrating that AI-supported decisions are suitable for regulated development.

Regional Insights: Infrastructure, Regulation, and Manufacturing Maturity

North America combines advanced cell and gene therapy research with established bioprocessing capabilities and strong demand for reproducible, scalable reagents. Europe emphasizes quality systems, traceability, and regulatory alignment across diverse national environments. Asia-Pacific is supported by expanding biomanufacturing capacity and research activity, with particularly important development centers in China, Japan, South Korea, India, and Australia. Latin America is shaped by uneven access to specialized infrastructure, local manufacturing development, and the need for cost-conscious process solutions. The Middle East is investing selectively in biotechnology and advanced healthcare capacity, while Africa's adoption is influenced by infrastructure availability, workforce development, and access to reliable cold-chain and laboratory systems.

Group Insights: Alliances Shape Standards, Access, and Capability

ASEAN countries present a varied combination of emerging biomanufacturing capacity, research networks, and regulatory maturity, creating opportunities for harmonized training and procurement practices. BRICS members span major research and production ecosystems as well as developing biotechnology markets, making technology transfer and local capability important considerations. The European Union benefits from regulatory coordination and cross-border scientific collaboration. G7 economies generally possess advanced research infrastructure and mature quality systems. GCC members are building biotechnology and healthcare capabilities through investment and institutional partnerships. NATO countries encompass a broad scientific and industrial base, with collaboration priorities that include supply resilience, biosafety, and trusted production capacity.

Country Insights: Diverse Adoption Priorities Across Major Markets

The United States and Canada emphasize translational research, commercial-scale bioprocessing, and stringent quality documentation. The United Kingdom, France, Germany, Italy, and Spain combine academic strength with growing advanced-therapy manufacturing, while European Union alignment supports common quality expectations. China is expanding domestic biotechnology capabilities and process-development capacity. Japan and South Korea prioritize high-quality manufacturing, automation, and precision process control. India is strengthening biopharmaceutical production and research while balancing cost efficiency with regulatory consistency. Australia supports advanced biomedical research and specialized manufacturing partnerships. Brazil and Mexico are important Latin American hubs where access, local production, workforce training, and technology transfer remain central. Russia's biotechnology activity is influenced by domestic supply priorities, research capacity, and evolving international cooperation conditions.

Actionable Priorities for Leaders in Viral-Vector Process Development

Industry leaders should evaluate enhancers through integrated design-of-experiments programs that measure transduction, viability, phenotype, vector integrity, and downstream product quality together. They should establish supplier qualification criteria covering composition, lot consistency, documentation, sterility or bioburden controls, and change-notification practices. Development teams should test performance across relevant cell sources and scales early, rather than optimizing only in small research formats. Regulatory and technical teams should maintain clear records of enhancer identity, use level, removal strategy, and risk assessment. Finally, organizations should build regional supply contingencies, invest in analytical comparability, and use AI only within governed workflows with validated data and human oversight.

Research Methodology: Evidence-Based Qualitative Market Assessment

This executive summary uses a structured qualitative assessment of the viral-transduction-enhancer field. The analysis organizes evidence around application needs, process-development challenges, regulatory and quality considerations, artificial-intelligence use cases, infrastructure conditions, and geographic biotechnology capabilities. Regional, group, and country observations are synthesized from broadly established industry and policy characteristics rather than from proprietary estimates. No market sizing, market-share calculation, forecast, or company-specific ranking is included. Conclusions should be interpreted as strategic context and validated against current scientific literature, regulatory guidance, procurement data, and organization-specific process results.

Conclusion: Reproducibility and Integration Will Define Competitive Relevance

Viral transduction enhancers are becoming more consequential as developers seek reliable delivery across complex cell and vector systems. The field's direction will be determined less by isolated increases in transduction than by the ability to deliver repeatable performance, protect cell health, support scalable manufacturing, and satisfy quality expectations. Regional capability, coordinated standards, resilient supply, and responsible use of AI will influence adoption. Leaders that connect enhancer selection with end-to-end process control and evidence generation will be better positioned to translate laboratory gains into robust therapeutic and biomanufacturing workflows.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Viral Transduction Enhancer Market, by Product Type

  • 7.1. Introduction
  • 7.2. Cationic Lipids
    • 7.2.1. Lipofectamine
    • 7.2.2. Transfectam
  • 7.3. Cationic Polymers
    • 7.3.1. DEAE-Dextran
    • 7.3.2. Polybrene
    • 7.3.3. Protamine Sulfate
  • 7.4. Dendrimers
  • 7.5. Peptide Based
    • 7.5.1. Chariot
    • 7.5.2. MPG

8. Viral Transduction Enhancer Market, by Vector Type

  • 8.1. Introduction
  • 8.2. AAV
    • 8.2.1. Self Complementary
    • 8.2.2. Single Stranded
  • 8.3. Adenoviral
    • 8.3.1. Replication Competent
    • 8.3.2. Replication Deficient
  • 8.4. Lentiviral
    • 8.4.1. First Generation
    • 8.4.2. Second Generation
    • 8.4.3. Third Generation
  • 8.5. Retroviral

9. Viral Transduction Enhancer Market, by Workflow Stage

  • 9.1. Introduction
  • 9.2. Downstream Processing
    • 9.2.1. Formulation
    • 9.2.2. Purification
  • 9.3. Quality Control
    • 9.3.1. Vector Integration Analysis
    • 9.3.2. Viability Testing
  • 9.4. Transduction
    • 9.4.1. Cell Culture
      • 9.4.1.1. Adherent
      • 9.4.1.2. Suspension
    • 9.4.2. Transduction Optimization
    • 9.4.3. Virus Production
      • 9.4.3.1. Amplification
      • 9.4.3.2. Titering
  • 9.5. Upstream Processing
    • 9.5.1. Cell Expansion
    • 9.5.2. Media Preparation

10. Viral Transduction Enhancer Market, by Application

  • 10.1. Introduction
  • 10.2. Ex Vivo
    • 10.2.1. Hematopoietic Stem Cell
    • 10.2.2. T Cell
  • 10.3. In Situ
  • 10.4. In Vivo
    • 10.4.1. Musculoskeletal
    • 10.4.2. Neurological
    • 10.4.3. Ocular

11. Viral Transduction Enhancer Market, by End User

  • 11.1. Introduction
  • 11.2. Academic Institutes
    • 11.2.1. Research Centers
    • 11.2.2. Universities
  • 11.3. Biopharmaceutical Companies
  • 11.4. Contract Research Organizations
    • 11.4.1. Clinical
    • 11.4.2. Preclinical
  • 11.5. Hospital Labs

12. Viral Transduction Enhancer Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Viral Transduction Enhancer Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Viral Transduction Enhancer Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Aldevron, LLC
  • 16.2. Applied Biological Materials Inc.
  • 16.3. Bio-Rad Laboratories
  • 16.4. Bio-Techne Corporation
  • 16.5. GenScript Biotech Corporation
  • 16.6. Horizon Discovery Group plc
  • 16.7. Lonza Group Ltd.
  • 16.8. MaxCyte
  • 16.9. Merck KGaA
  • 16.10. Miltenyi Biotec GmbH
  • 16.11. Mirus Bio
  • 16.12. Oxford Biomedica plc
  • 16.13. OZ Biosciences
  • 16.14. Polyplus-transfection SA
  • 16.15. Promega Corporation
  • 16.16. Revvity
  • 16.17. Sino Biological Inc.
  • 16.18. SIRION Biotech GmbH
  • 16.19. TaKaRa Bio Inc.
  • 16.20. Thermo Fisher Scientific Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Viral Transduction Enhancer Market, Years Considered for the Study
  • FIGURE 2. Global Viral Transduction Enhancer Market, Research Design
  • FIGURE 3. Global Viral Transduction Enhancer Market, Research Framework
  • FIGURE 4. Global Viral Transduction Enhancer Market, Data Triangulation
  • FIGURE 5. Global Viral Transduction Enhancer Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Viral Transduction Enhancer Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Viral Transduction Enhancer Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Viral Transduction Enhancer Market Size, by Vector Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Viral Transduction Enhancer Market Size, by Vector Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Viral Transduction Enhancer Market Size, by Workflow Stage, 2025 vs 2032 (%)
  • FIGURE 11. Global Viral Transduction Enhancer Market Size, by Workflow Stage, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Viral Transduction Enhancer Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global Viral Transduction Enhancer Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Viral Transduction Enhancer Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Viral Transduction Enhancer Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Viral Transduction Enhancer Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Viral Transduction Enhancer Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Viral Transduction Enhancer Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Viral Transduction Enhancer Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Viral Transduction Enhancer Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Viral Transduction Enhancer Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Viral Transduction Enhancer Market Segmentation & Coverage
  • TABLE 2. Global Viral Transduction Enhancer Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Cationic Lipids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Cationic Lipids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Cationic Lipids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Lipofectamine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Lipofectamine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Lipofectamine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Transfectam Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Transfectam Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Transfectam Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Cationic Polymers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Cationic Polymers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Cationic Polymers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global DEAE-Dextran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global DEAE-Dextran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global DEAE-Dextran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Polybrene Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Polybrene Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Polybrene Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Protamine Sulfate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Protamine Sulfate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Protamine Sulfate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Dendrimers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Dendrimers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Dendrimers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Peptide Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Peptide Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Peptide Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Chariot Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Chariot Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Chariot Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global MPG Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global MPG Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global MPG Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 38. Global AAV Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global AAV Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global AAV Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Self Complementary Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Self Complementary Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Self Complementary Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Single Stranded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Single Stranded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Single Stranded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Adenoviral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Adenoviral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Adenoviral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Replication Competent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Replication Competent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Replication Competent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Replication Deficient Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Replication Deficient Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Replication Deficient Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Lentiviral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Lentiviral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Lentiviral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global First Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global First Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global First Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Second Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Second Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Second Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Third Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Third Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Third Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Retroviral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Retroviral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Retroviral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 72. Global Downstream Processing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Downstream Processing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Downstream Processing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Purification Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Purification Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Purification Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Quality Control Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Quality Control Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Quality Control Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Vector Integration Analysis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Vector Integration Analysis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Vector Integration Analysis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Viability Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Viability Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Viability Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Transduction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Transduction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Transduction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global Cell Culture Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global Cell Culture Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global Cell Culture Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Adherent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global Adherent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global Adherent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 102. Global Transduction Optimization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. Global Transduction Optimization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. Global Transduction Optimization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 105. Global Virus Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Global Virus Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 107. Global Virus Production Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 108. Global Amplification Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 109. Global Amplification Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. Global Amplification Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 111. Global Titering Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 112. Global Titering Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. Global Titering Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 114. Global Upstream Processing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Upstream Processing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Upstream Processing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global Cell Expansion Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Global Cell Expansion Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. Global Cell Expansion Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 120. Global Media Preparation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Global Media Preparation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. Global Media Preparation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 123. Global Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 124. Global Ex Vivo Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 125. Global Ex Vivo Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 126. Global Ex Vivo Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 127. Global Hematopoietic Stem Cell Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Global Hematopoietic Stem Cell Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 129. Global Hematopoietic Stem Cell Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 130. Global T Cell Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 131. Global T Cell Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. Global T Cell Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 133. Global In Situ Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Global In Situ Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 135. Global In Situ Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 136. Global In Vivo Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 137. Global In Vivo Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 138. Global In Vivo Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 139. Global Musculoskeletal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 140. Global Musculoskeletal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. Global Musculoskeletal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 142. Global Neurological Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Global Neurological Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. Global Neurological Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 145. Global Ocular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Global Ocular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. Global Ocular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 148. Global Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 149. Global Academic Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. Global Academic Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. Global Academic Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 152. Global Research Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 153. Global Research Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 154. Global Research Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 155. Global Universities Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 156. Global Universities Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 157. Global Universities Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 158. Global Biopharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 159. Global Biopharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 160. Global Biopharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 161. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 162. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 163. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 164. Global Clinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 165. Global Clinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 166. Global Clinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 167. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 168. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 169. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 170. Global Hospital Labs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 171. Global Hospital Labs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 172. Global Hospital Labs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 173. Global Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 174. Asia-Pacific Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 175. Asia-Pacific Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 176. Asia-Pacific Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 177. Asia-Pacific Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 178. Asia-Pacific Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 179. Asia-Pacific Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 180. Asia-Pacific Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 181. Asia-Pacific Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 182. Asia-Pacific Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 183. Asia-Pacific Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 184. Asia-Pacific Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 185. Asia-Pacific Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 186. Asia-Pacific Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 187. Asia-Pacific Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 188. Asia-Pacific Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 189. Asia-Pacific Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 190. Asia-Pacific Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 191. Asia-Pacific Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 192. Asia-Pacific Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 193. Asia-Pacific Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. Asia-Pacific Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 195. Asia-Pacific Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 196. North America Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 197. North America Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 198. North America Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 199. North America Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 200. North America Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 201. North America Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 202. North America Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 203. North America Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 204. North America Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 205. North America Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 206. North America Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 207. North America Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 208. North America Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 209. North America Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 210. North America Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 211. North America Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 212. North America Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 213. North America Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 214. North America Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 215. North America Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 216. North America Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 217. North America Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 218. Latin America Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 219. Latin America Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 220. Latin America Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 221. Latin America Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 222. Latin America Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 223. Latin America Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 224. Latin America Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 225. Latin America Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 226. Latin America Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 227. Latin America Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 228. Latin America Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 229. Latin America Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 230. Latin America Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 231. Latin America Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 232. Latin America Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 233. Latin America Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 234. Latin America Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 235. Latin America Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 236. Latin America Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 237. Latin America Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 238. Latin America Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 239. Latin America Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 240. Europe Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 241. Europe Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 242. Europe Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 243. Europe Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 244. Europe Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 245. Europe Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 246. Europe Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 247. Europe Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 248. Europe Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 249. Europe Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 250. Europe Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 251. Europe Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 252. Europe Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 253. Europe Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 254. Europe Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 255. Europe Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 256. Europe Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 257. Europe Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 258. Europe Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 259. Europe Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 260. Europe Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 261. Europe Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 262. Middle East Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 263. Middle East Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 264. Middle East Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 265. Middle East Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 266. Middle East Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 267. Middle East Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 268. Middle East Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 269. Middle East Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 270. Middle East Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 271. Middle East Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 272. Middle East Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 273. Middle East Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 274. Middle East Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 275. Middle East Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 276. Middle East Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 277. Middle East Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 278. Middle East Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 279. Middle East Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 280. Middle East Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 281. Middle East Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 282. Middle East Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 283. Middle East Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 284. Africa Viral Transduction Enhancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 285. Africa Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 286. Africa Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 287. Africa Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 288. Africa Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 289. Africa Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 290. Africa Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 291. Africa Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 292. Africa Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 293. Africa Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 294. Africa Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 295. Africa Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 296. Africa Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 297. Africa Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 298. Africa Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 299. Africa Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 300. Africa Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 301. Africa Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 302. Africa Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 303. Africa Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 304. Africa Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 305. Africa Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 306. Global Viral Transduction Enhancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 307. ASEAN Viral Transduction Enhancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 308. ASEAN Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 309. ASEAN Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 310. ASEAN Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 311. ASEAN Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 312. ASEAN Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 313. ASEAN Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 314. ASEAN Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 315. ASEAN Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 316. ASEAN Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 317. ASEAN Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 318. ASEAN Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 319. ASEAN Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 320. ASEAN Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 321. ASEAN Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 322. ASEAN Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 323. ASEAN Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 324. ASEAN Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 325. ASEAN Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 326. ASEAN Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 327. ASEAN Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 328. ASEAN Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 329. GCC Viral Transduction Enhancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 330. GCC Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 331. GCC Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 332. GCC Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)
  • TABLE 333. GCC Viral Transduction Enhancer Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 334. GCC Viral Transduction Enhancer Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 335. GCC Viral Transduction Enhancer Market Size, by AAV, 2017-2032 (USD Million)
  • TABLE 336. GCC Viral Transduction Enhancer Market Size, by Adenoviral, 2017-2032 (USD Million)
  • TABLE 337. GCC Viral Transduction Enhancer Market Size, by Lentiviral, 2017-2032 (USD Million)
  • TABLE 338. GCC Viral Transduction Enhancer Market Size, by Workflow Stage, 2017-2032 (USD Million)
  • TABLE 339. GCC Viral Transduction Enhancer Market Size, by Downstream Processing, 2017-2032 (USD Million)
  • TABLE 340. GCC Viral Transduction Enhancer Market Size, by Quality Control, 2017-2032 (USD Million)
  • TABLE 341. GCC Viral Transduction Enhancer Market Size, by Transduction, 2017-2032 (USD Million)
  • TABLE 342. GCC Viral Transduction Enhancer Market Size, by Cell Culture, 2017-2032 (USD Million)
  • TABLE 343. GCC Viral Transduction Enhancer Market Size, by Virus Production, 2017-2032 (USD Million)
  • TABLE 344. GCC Viral Transduction Enhancer Market Size, by Upstream Processing, 2017-2032 (USD Million)
  • TABLE 345. GCC Viral Transduction Enhancer Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 346. GCC Viral Transduction Enhancer Market Size, by Ex Vivo, 2017-2032 (USD Million)
  • TABLE 347. GCC Viral Transduction Enhancer Market Size, by In Vivo, 2017-2032 (USD Million)
  • TABLE 348. GCC Viral Transduction Enhancer Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 349. GCC Viral Transduction Enhancer Market Size, by Academic Institutes, 2017-2032 (USD Million)
  • TABLE 350. GCC Viral Transduction Enhancer Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 351. European Union Viral Transduction Enhancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 352. European Union Viral Transduction Enhancer Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 353. European Union Viral Transduction Enhancer Market Size, by Cationic Lipids, 2017-2032 (USD Million)
  • TABLE 354. European Union Viral Transduction Enhancer Market Size, by Cationic Polymers, 2017-2032 (USD Million)